- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
J&J sees recovery in coronavirus-hit medical devices unit at end of year
US: Johnson & Johnson on Tuesday said it expects its medical device business to begin recovering in the fourth quarter as elective medical procedures delayed by the coronavirus pandemic start to resume.
The U.S. healthcare conglomerate lowered its full-year 2020 forecast due to the hit to its medical device business with procedures like hip and knee replacements on hold. The division accounts for nearly 30% of its total quarterly sales.
However, investors appeared to take heart that J&J did not simply withdraw its 2020 forecasts over coronavirus uncertainty as the pandemic causes massive business disruptions around the world. It also raised the quarterly dividend to $1.01 per share, and its shares rose 5% to $146.89
J&J's forecast for 2020 adjusted earnings of $7.50 to $7.90 per share - down from its prior estimate of $8.95 to $9.10 - assumes that a return of the coronavirus outbreak in the fall will look much different than the current global health crisis.
"If the virus does return, the world should be much better prepared to test, identify and isolate it. There may also be therapeutic options available," Chief Financial Officer Joseph Wolk said on a conference call.
Wolk said he expected elective procedures and doctor visits would be largely allowed in the second half of the year, with the business seeing a lingering impact but starting to stabilize in the third quarter.
Drugmakers and medical researchers are racing to develop treatments and vaccines for the novel coronavirus, which has infected some 2 million people globally.
J&J is developing a coronavirus vaccine and plans to start human trials by September, with an eye on having it ready under an emergency use authorization in early 2021.
J&J Chief Executive Alex Gorsky said the company was developing the vaccine on a "not-for-profit" basis for emergency pandemic use.
J&J, the first major U.S. drugmaker to report earnings since the outbreak, said medical device sales in the first quarter fell 8.2% to $5.93 billion, with products used in high-margin orthopedic procedures and vision correction hit particularly hard.
Pharmaceutical sales rose 8.7% to $11.13 billion, helped by demand for cancer drugs Darzalex and Imbruvica.
Consumer health sales jumped 9.2% to $3.63 billion, driven by a surge in demand for products like Tylenol and Motrin as consumers faced with an illness that causes fever and cough stocked up on essentials.
Excluding items, J&J earned $2.30 per share, beating the average analyst estimate by 30 cents, according to IBES data from Refinitiv.
Read also: Johnson & Johnson Announces A Lead Vaccine Candidate For COVID-19; To Supply One Billion Vaccines
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.